Consequently, in CKD-associated hypertension, GDF-15 may exert its influence through multiple pathways, which encompass not only the regulatory mechanisms activated by renal impairment but also potential pharmacological mechanisms involving receptor desensitization and saturation. This evidence concerns the gene GDF15 and hypertensive disorder.